MapLight Therapeutics (MPLT) Proxy filing summary

Executive summary

• The annual meeting is scheduled for June 23, 2026, to be held virtually, with voting on director elections and auditor ratification.

• Stockholders of record as of April 27, 2026, are eligible to vote, with 42,610,079 shares outstanding.

• Voting can be conducted online, by phone, or by mail, and stockholders may revoke proxies before the meeting.

Voting matters and shareholder proposals

• Proposal 1: Election of three Class I directors (Martin Babler, Troy Cox, George Pavlov) for terms expiring in 2029.

• Proposal 2: Ratification of RSM US LLP as independent auditor for the year ending December 31, 2026.

• Board recommends voting FOR all director nominees and FOR auditor ratification.

• Shareholders may submit proposals for the 2027 meeting between February 23 and March 25, 2027.

Board of directors and corporate governance

• Board consists of seven members divided into three classes, with a majority deemed independent under Nasdaq standards.

• George Pavlov serves as independent, non-executive Chair; committee chairs are independent.

• Three standing committees: Audit, Compensation, and Nominating and Corporate Governance, each with defined charters and independence.

• Board met 11 times in the last fiscal year; all members attended at least 75% of meetings.

• Code of Business Conduct and Ethics and Corporate Governance Guidelines are in place and available online.